Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 5—May 2014
Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 5

Characteristics associated with expert consultation for 134 patients during MDR TB treatment, California, Texas, and New York, NY, USA, 2005–2007*†

Variable Initial OR estimate Initial 95% CI Initial Pr>χ2 Final OR estimate Final 95% CI Final Pr>χ2
XDR TB >999.999 <0.001–>999.999 0.939
Recent homelessness >999.999 <0.001–>999.999 0.887
Correctional institution residence >999.999 <0.001–>999.999 0.939
Recent injection drug or noninjection drug use 61.63 0.00–>999.999 0.401
Recent cigarette smoker 27.88 0.56–>999.999 0.096
Diabetes 26.44 1.28–545.80 0.034
Disseminated TB disease 9.49 0.18–501.11 0.266
TB clinic outpatient management 7.96 1.50–42.32 0.015 5.67 1.93–16.64 0.002
Age 45–64 y 4.30 0.38–48.55 0.239
Recent unemployment 3.81 0.52–28.18 0.190
Age 25–44 years 2.92 0.58–14.63 0.192
Long-term care facility resident 1.87 <0.001–>999.999 0.878
5-drug regimen 1.13 0.22–5.82 0.882
Total no. adverse events 1.12 0.88–1.42 0.371
Total first-line resistance 0.63 0.11–3.77 0.614
Acquired resistance 0.57 0.07–4.37 0.588
Foreign born 0.55 0.03–12.28 0.705
History of TB disease 0.53 0.13–2.10 0.363
Age >65 y 0.50 0.02–14.97 0.687
HIV infection 0.34 0.02–7.21 0.492
Pregnant 0.28 0.02–5.15 0.393
Private insurance 0.14 0.02–0.87 0.035 0.23 0.08–0.68 0.008
Pre-XDR 0.12 0.01–1.35 0.087
Male 0.12 0.02–0.82 0.031
Died 0.05 <0.001–3.46 0.165
White race 0.05 <0.001–>999.999 0.988
Recent excess alcohol use <0.001 <0.001–0.06 0.002 0.19 0.05–0.72 0.014
Black race <0.001 <0.001–>999.999 0.937
Hispanic ethnicity <0.001 <0.001–>999.999 0.938
Asian race <0.001 <0.001–>999.999 0.943

*MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB; OR, odds ratio. Boldface indicates significance in the final model. Blank cells indicate variables not retained in the final model.
†Model fit intercept and covariates: AIC (initial 133.402, final 121.683), SC (initial 223.235, final 133.274); –2logL (initial 71.402, final 113.683).

Main Article

Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external